Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
OX40 is a potent immune-stimulating target in late-stage cancer patients.
Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwsen T, Fox BA, Moudgil T, Miller W, Haley D, Coffey T, Fisher B, Delanty-Miller L, Rymarchyk N, Kelly T, Crocenzi T, Bernstein E, Sanborn R, Urba WJ, Weinberg AD. Curti BD, et al. Cancer Res. 2013 Dec 15;73(24):7189-7198. doi: 10.1158/0008-5472.CAN-12-4174. Epub 2013 Oct 31. Cancer Res. 2013. PMID: 24177180 Free PMC article. Clinical Trial.
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.
Dandamudi UB, Ghebremichael M, Sosman JA, Clark JI, McDermott DF, Atkins MB, Dutcher JP, Urba WJ, Regan MM, Puzanov I, Crocenzi TS, Curti BD, Vaishampayan UN, Crosby NA, Margolin KA, Ernstoff MS. Dandamudi UB, et al. Among authors: crocenzi ts. J Immunother. 2013 Nov-Dec;36(9):490-5. doi: 10.1097/CJI.0000000000000003. J Immunother. 2013. PMID: 24145360 Clinical Trial.
Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.
Petrausch U, Poehlein CH, Jensen SM, Twitty C, Thompson JA, Assmann I, Puri S, LaCelle MG, Moudgil T, Maston L, Friedman K, Church S, Cardenas E, Haley DP, Walker EB, Akporiaye E, Weinberg AD, Rosenheim S, Crocenzi TS, Hu HM, Curti BD, Urba WJ, Fox BA. Petrausch U, et al. Among authors: crocenzi ts. Curr Mol Med. 2009 Aug;9(6):673-82. doi: 10.2174/156652409788970670. Curr Mol Med. 2009. PMID: 19689294 Free PMC article. Review.
A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma.
Crocenzi T, Cottam B, Newell P, Wolf RF, Hansen PD, Hammill C, Solhjem MC, To YY, Greathouse A, Tormoen G, Jutric Z, Young K, Bahjat KS, Gough MJ, Crittenden MR. Crocenzi T, et al. J Immunother Cancer. 2016 Aug 16;4:45. doi: 10.1186/s40425-016-0149-6. eCollection 2016. J Immunother Cancer. 2016. PMID: 27532020 Free PMC article.
Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
Martin RC 2nd, Scoggins CR, Schreeder M, Rilling WS, Laing CJ, Tatum CM, Kelly LR, Garcia-Monaco RD, Sharma VR, Crocenzi TS, Strasberg SM. Martin RC 2nd, et al. Among authors: crocenzi ts. Cancer. 2015 Oct 15;121(20):3649-58. doi: 10.1002/cncr.29534. Epub 2015 Jul 6. Cancer. 2015. PMID: 26149602 Free article. Clinical Trial.
A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.
Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika AC, Osada T, Onaitis M, Clary BM, Hsu D, Devi GR, Bulusu A, Annechiarico RP, Chadaram V, Clay TM, Lyerly HK. Morse MA, et al. Among authors: crocenzi ts. Ann Surg. 2013 Dec;258(6):879-86. doi: 10.1097/SLA.0b013e318292919e. Ann Surg. 2013. PMID: 23657083 Free PMC article. Clinical Trial.
Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery.
Gunturu KS, Meehan KR, Mackenzie TA, Crocenzi TS, McDermott D, Usherwood EJ, Margolin KA, Crosby NA, Atkins MB, Turk MJ, Ahonen C, Fuse S, Clark JI, Fisher JL, Noelle RJ, Ernstoff MS. Gunturu KS, et al. Among authors: crocenzi ts. J Clin Oncol. 2010 Mar 1;28(7):1196-202. doi: 10.1200/JCO.2009.24.8153. Epub 2010 Feb 1. J Clin Oncol. 2010. PMID: 20124177 Free PMC article. Clinical Trial.
Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang.
Ernstoff MS, Crocenzi TS, Seigne JD, Crosby NA, Cole BF, Fisher JL, Uhlenhake JC, Mellinger D, Foster C, Farnham CJ, Mackay K, Szczepiorkowski ZM, Webber SM, Schned AR, Harris RD, Barth RJ Jr, Heaney JA, Noelle RJ. Ernstoff MS, et al. Among authors: crocenzi ts. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):733s-740s. doi: 10.1158/1078-0432.CCR-06-2064. Clin Cancer Res. 2007. PMID: 17255302 Review.
29 results